Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
about
Cytomegalovirus infection in transplant recipientsCytomegalovirus and Aspergillus spp. coinfection in organ transplantation: a case report and review of the literaturePerivascular stromal cells as a potential reservoir of human cytomegalovirus.Cytomegalovirus latency and reactivation: recent insights into an age old problem.Recent advances in designing an effective vaccine to prevent cytomegalovirus-associated clinical diseases.Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency.Human cytomegalovirus activation of ERK and myeloid cell leukemia-1 protein correlates with survival of latently infected cells.Human cytomegalovirus-specific T-cell immune reconstitution in preemptively treated heart transplant recipients identifies subjects at critical risk for infectionEfficient human cytomegalovirus reactivation is maturation dependent in the Langerhans dendritic cell lineage and can be studied using a CD14+ experimental latency model.Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of Cancer-Norfolk cohort.24 weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience.Toll-like receptor signaling in transplantation.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Chromatin-mediated regulation of cytomegalovirus gene expression.Immune response to CMV in solid organ transplant recipients: current concepts and future directions.Human cytomegalovirus manipulation of latently infected cells.The intimate relationship between human cytomegalovirus and the dendritic cell lineage.Early stage of cytomegalovirus infection suppresses host microRNA expression regulation in human fibroblasts.Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells.Easier Control of Late-Onset Cytomegalovirus Disease Following Universal Prophylaxis Through an Early Antiviral Immune Response in Donor-Positive, Recipient-Negative Kidney Transplants.Human cytomegalovirus inhibits apoptosis involving upregulation of the antiapoptotic protein Bag-1.Human Cytomegalovirus Delays Neutrophil Apoptosis and Stimulates the Release of a Prosurvival Secretome.Rapamycin does not inhibit human cytomegalovirus reactivation from dendritic cells in vitro.Myeloid Dendritic Cells Repress Human Cytomegalovirus Gene Expression and Spread by Releasing Interferon-Unrelated Soluble Antiviral Factors.Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies.A Virally Encoded DeSUMOylase Activity Is Required for Cytomegalovirus Reactivation from Latency
P2860
Q26801802-9CF3418E-BF23-4C6B-B19A-9CE2783B6548Q33628293-17251ABE-A51F-46AC-B716-186F4197D7C6Q33714313-33C9B61F-B7CB-41CE-8725-C70C6F759723Q33761454-28BAB92D-FE13-438E-8E24-79E838764D7EQ34349745-9B4E3327-3AD4-4CCC-B788-43282EEBA3FAQ35191037-3A7E95CA-24B2-4F10-9533-07BABD05EEFAQ35673697-FF27EDBD-CA25-49ED-90B3-2C34BBFE7741Q36023008-B60257F4-85AF-4228-9255-9CC23B698054Q36171970-68E5DCF6-0570-4FFE-B8D4-4DA5A712A15CQ36789917-585061A4-4524-4074-992E-13F5FD325E88Q36929597-D1CF6EB3-AD94-41DF-8FE5-FF80BC1264A6Q37236946-65BC95BC-36C1-4C9E-8810-5E24E52B28C4Q37680941-A2E61E7B-5FCA-4B4C-9295-BE14A5BEE5CEQ37793472-F77FABED-053E-4CD9-85E2-9CC68D8421F0Q38011227-9ACE3CA5-555F-46A6-8544-ADCAB0260BB2Q38166925-458A6FB1-95AC-40C0-896E-A882A2DC5F59Q38242199-485DC2C2-C416-4A8E-9814-F2B680DEDC8CQ38723034-A17A430E-AF86-4D72-892F-6559A4BCB613Q38960892-F0718C3F-DC65-4851-89F1-3F87D37838C8Q40763966-8E582391-B824-42FE-8184-1F59D62D055BQ40822984-CB053658-96F5-44D1-BCC7-59DF81E82193Q41921179-F30CD44B-CBDB-4B4D-B9EC-19E30A8ECB5CQ42208780-08331319-D041-4197-B789-4AF1B663F0B1Q47607938-239ED208-6E0F-4ED6-957F-12D775BD7277Q52568669-E009BAAB-A439-4ED7-80B4-27CFB0F8EE0AQ57019856-C4F61480-043A-43C2-9F0F-C1BB148D6949
P2860
Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Improving outcomes for solid-o ...... ase and indirect consequences.
@en
Improving outcomes for solid-o ...... ase and indirect consequences.
@nl
type
label
Improving outcomes for solid-o ...... ase and indirect consequences.
@en
Improving outcomes for solid-o ...... ase and indirect consequences.
@nl
prefLabel
Improving outcomes for solid-o ...... ase and indirect consequences.
@en
Improving outcomes for solid-o ...... ase and indirect consequences.
@nl
P2860
P356
P1476
Improving outcomes for solid-o ...... ase and indirect consequences.
@en
P2093
Christophe Legendre
Manuel Pascual
P2860
P304
P356
10.1086/527397
P407
P577
2008-03-01T00:00:00Z